HARBOR study shows sustained visual gains at 2 years

Visual and anatomic outcomes from ranibizumab injection for subfoveal neovascular age-related macular degeneration were maintained between 12 months and 24 months, according to the HARBOR study.Monthly and as-needed injections of Lucentis (ranibizumab, Genentech) proved similarly effective, with safety profiles comparable to previous studies, according to Allen C. Ho, MD, the corresponding author and OSN Retina/Vitreous Board Member.